

Sent by email to: [REDACTED]

[REDACTED]
[REDACTED]
Leukaemia CARE
One Birch Court
Blackpole East
Worcester
WR3 8SG

4 October 2017

Dear [REDACTED]

Appeal against Final Appraisal Determination (FAD): Inotuzumab ozogamicin for treating relapsed or refractory B cell acute lymphoblastic leukaemia

Thank you for lodging your appeal against the above Final Appraisal Determination. I acknowledge receipt of your email dated 27 September 2017 confirming that you are happy to proceed with the response in my initial scrutiny letter. We will use your appeal letter and the initial scrutiny letter for the appeal.

Yours sincerely

Dr Rosie Benneworth
Vice Chair
National Institute for Health and Care Excellence